Earnings call transcript: Vivos Therapeutics reports Q1 2025 earnings, stock rises
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed financial performance, with declining total revenue and gross margins, and an increase in operating loss. While there are positive developments, such as the SCN acquisition and potential revenue growth, the company's financial health is concerning, with significant cash burn and increased operational expenses. The Q&A section highlighted management's vague responses regarding financial impact, raising concerns. Given these factors, the stock price is likely to react negatively in the short term, with a potential decline between -2% to -8%.
Key Financial Performance
Total Revenue $3,000,000 (down 12% year-over-year from $3,400,000); decrease due to lower service revenue, particularly from VIP enrollments.
Product Revenue $1,800,000 (up 8% year-over-year from $1,700,000); increase attributed to higher sales volume of pediatric products.
Gross Profit $1,500,000 (down from $1,900,000 year-over-year); decrease primarily due to lower revenue, partially offset by decreased cost of sales.
Gross Margin 50% (down from 57% year-over-year); decrease due to the decline in VIP service revenue.
Sales and Marketing Expenses $400,000 (down from $700,000 year-over-year); decrease reflects lower sales commissions and marketing expenses due to the new marketing strategy.
General and Administrative Expenses $4,900,000 (unchanged year-over-year); slight decrease of 1%.
Total Operating Expenses $5,300,000 (down $300,000 or 5% year-over-year); decrease due to cost-cutting initiatives.
Operating Loss $3,900,000 (slightly up from $3,800,000 year-over-year); slight increase due to lower total sales offset by lower operating expenses.
Net Loss $3,900,000 (compared to a loss of $3,800,000 year-over-year); consistent with the operating loss.
Cash Used in Operations $3,800,000 (up $1,300,000 year-over-year from $2,500,000); increase due to reduction in contract liability and decrease in accrued expenses.
Cash and Cash Equivalents $2,300,000 (down from $6,300,000 as of 12/31/2024); decrease reflects cash burn and operational expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Product Sales Growth: Product sales increased by 8% in Q1 2025, attributed to higher volume in sales of pediatric guide appliances.
Total Arches Shipped: Total arches shipped grew 87% from 1,996 in Q1 2024 to 3,736 in Q1 2025.
Acquisition of Sleep Center of Nevada: Vivo expects to close the acquisition of Sleep Center of Nevada (SCN) in the next month or two, which is anticipated to be accretive to revenue and gross profit.
Patient Volume from SCN: SCN sees approximately 3,000 sleep patients a month, with 90% testing positive for OSA.
Cost Reduction: Sales and marketing expenses decreased from $700,000 in Q1 2024 to $400,000 in Q1 2025 due to the pivot in marketing strategy.
Operational Efficiency: Vivo's operations team is prepared to generate revenue immediately after the SCN acquisition, with over 100 patient visits already booked.
Business Model Pivot: Vivo is transitioning to a model of strategic alliances and acquisitions of sleep medical providers to drive sales and diversify revenue.
Future Growth Strategy: Vivo is actively exploring additional acquisition opportunities in the sleep medicine sector, with positive reception from potential partners.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: Vivo Therapeutics operates under FDA regulations, and while they have received FDA clearance for certain appliances, any changes in regulatory requirements could impact their operations and product offerings.
Acquisition Risks: The pending acquisition of the Sleep Center of Nevada (SCN) carries risks related to integration and operational execution. Delays or issues in the integration process could affect expected revenue and profitability.
Financial Risks: Vivo is currently experiencing cash burn, with a net loss of $3.9 million in Q1 2025. The company is reliant on securing financing to close the SCN acquisition and bolster its cash position.
Market Competition: Vivo faces competitive pressures in the sleep medicine market, particularly from established players in the field. Their ability to capture market share and patient acceptance rates will be critical.
Operational Challenges: The transition to a new business model focusing on strategic alliances and acquisitions may present operational challenges, including the need for effective management of new partnerships and integration of services.
Economic Factors: Economic conditions affecting healthcare spending and patient willingness to seek treatment could impact Vivo's revenue generation and growth prospects.
Patient Volume Risks: The success of the SCN acquisition is contingent on the ability to convert a significant portion of the 3,000 patients tested monthly into customers for Vivo's treatment, which may not materialize as expected.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Acquisition of Sleep Center of Nevada (SCN): Expected to close in the next month or two, anticipated to be accretive to revenue and gross profit, with SCN seeing approximately 3,000 sleep patients a month.
Strategic Alliances and Acquisitions: Vivo is actively exploring additional strategic alliances and acquisitions in the sleep medicine sector, with several negotiations in advanced stages.
Transition to New Business Model: Vivo is pivoting to a model focused on strategic alliances with sleep medical providers to drive sales and diversify revenue streams.
Revenue Growth Expectations: Expecting to generate significant positive cash flows and profits by the end of 2025, particularly through the SCN acquisition.
Patient Conversion Rates: Expecting to convert a significant portion of SCN's patients to Vivos treatment, similar to the 71% conversion rate seen with Rebus Health.
Revenue Projections: Total revenue for Q1 2025 was $3,000,000, with expectations for revenue growth following the SCN acquisition.
Operating Expenses: Anticipated increase in operating expenses in Q3 and Q4 due to hiring and training staff for SCN.
Cash Flow Expectations: Expecting to turn cash flow positive by Q3 2025 following the SCN acquisition.
Loan and Financing: Signed a non-binding term sheet for a $7,500,000 senior loan to facilitate the SCN acquisition and working capital.
Gross Profit Margin: Expected net contribution margins for SCN revenue projected to be 50% or better.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Senior Loan: Vivo Therapeutics signed a non-binding term sheet for a $7,500,000 senior loan to close the acquisition of Sleep Center of Nevada and for working capital.
Equity Infusion: The lender requires a simultaneous equity infusion of at least $1,500,000 as part of the SCN closing.
Acquisition Price: The acquisition price for Sleep Center of Nevada is $9,000,000, with $6,000,000 in cash and the remainder in equity and performance-based incentives.
Expected Revenue from SCN: SCN sees approximately 3,000 sleep patients a month, with a significant portion expected to convert to Vivos treatment.
Revenue per Case: The average revenue per case from Vivos treatment is expected to exceed $4,500.
Net Contribution Margin: The net contribution margins for SCN revenue are expected to be 50% or better.
Accretion Timeline: The acquisition is expected to be accretive to revenue and gross profit in the near term, with significant revenue expected by Q3 2025.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you expand on the experience with the Rebus Alliance and its contribution compared to expectations?
A:The experience with Rebus has gone slower than expected due to internal management issues on their side, resulting in lower patient referrals than anticipated. However, we proved our thesis that a significant percentage of patients (71%) prefer VIVOS treatment over CPAP, which encourages us for the upcoming SCN acquisition.
Q:What can you take away from the Rebus experience for future negotiations with potential partners?
A:We learned to optimize revenues and services in a medical insurance environment and have modified our agreements to ensure better control over patient flow and avoid roadblocks.
Q:What impact will the SCN acquisition have on the P&L, and when will it become accretive?
A:The SCN acquisition will add legacy revenue and expenses, but it is expected to be accretive due to the high volume of patients. We anticipate seeing revenue in Q3.
Q:Will operating expenses increase in Q3 and Q4 due to the acquisition?
A:Yes, we expect an uptick in operating expenses as we hire and train new staff, but revenue growth will quickly outpace these costs.
Q:How was the acquisition price of $9 million determined?
A:The price was based on a quality of earnings report and the potential patient volume. We negotiated a fair price that aligns incentives for the seller.
Q:Review of Unclear Management Responses
A:Management appeared to avoid giving a direct answer regarding the specific financial impact of the SCN acquisition on the P&L, particularly in terms of exact revenue figures for Q3 and the timeline for achieving profitability.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Ascendiant Capital
Capital Markets
Center Nevada
Doctor Prabhu
Hi
Las Vegas
Rebus patient
SCN
Sleep Center
Vegas number
acquisition Huntsman
analysis
appointment
beginning
combination
concentration
core
employee
equity partner
facility
funnel
gentleman Huntsman
legacy
lot Rebus
number patient
patient VIVOS
patient basis
patient market
patient price
percent patient
price patient
sale cost
standpoint
test
thesis
VVOS Transcript
Vivos Therapeutics, Inc. (VVOS) Q4 2025 Earnings Call Transcript
Unknown4-15
The earnings call reveals significant financial challenges: a 50.5% increase in operating expenses, a widened net loss, and substantial liabilities, which overshadow the 17% gross profit increase. The Q&A section highlights revenue drops due to provider absences and an unclear path to cash flow positivity. While there are growth prospects with new models and partnerships, the immediate financial health and guidance issues, coupled with increased debt, suggest a negative stock price reaction.
Vivos Therapeutics, Inc. (VVOS) Q3 2025 Earnings Call Transcript
Unknown11-19
The earnings call presents a mixed picture. While there is a significant revenue growth and expansion plans, concerns remain about cash flow and profitability due to ongoing net losses and high expenses. The Q&A section reveals optimism for future growth but lacks specific timelines for breakeven, which could worry investors. The slight decrease in gross margin and the substantial net loss further contribute to a neutral sentiment. Without market cap data, the impact on stock price is uncertain, but the lack of clear guidance tempers the positive elements.
Vivos Therapeutics, Inc. (VVOS) Q2 2025 Earnings Call Transcript
Unknown8-22
The earnings call reveals several concerns: a 6% revenue decline, increased operating losses, high acquisition costs, and cash flow challenges. Despite potential long-term benefits from acquisitions and strategic alliances, the immediate financial strain and reliance on debt raise red flags. No positive shareholder return plan was discussed, and the Q&A section did not clarify management's responses. Without a market cap, the stock's volatility is uncertain, but the financial issues suggest a negative short-term outlook.
Earnings call transcript: Vivos Therapeutics reports Q1 2025 earnings, stock rises
Unknown5-15
The earnings call reveals mixed financial performance, with declining total revenue and gross margins, and an increase in operating loss. While there are positive developments, such as the SCN acquisition and potential revenue growth, the company's financial health is concerning, with significant cash burn and increased operational expenses. The Q&A section highlighted management's vague responses regarding financial impact, raising concerns. Given these factors, the stock price is likely to react negatively in the short term, with a potential decline between -2% to -8%.
VVOS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
